Cigna Group (NYSE:CI) Stock Rating Lowered by Wall Street Zen

Cigna Group (NYSE:CI) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages have also weighed in on CI. UBS Group lifted their target price on shares of Cigna Group from $375.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Jefferies Financial Group lowered their price objective on shares of Cigna Group from $333.00 to $330.00 and set a “buy” rating for the company in a report on Monday, April 20th. Piper Sandler cut their price objective on Cigna Group from $370.00 to $346.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Morgan Stanley upped their target price on Cigna Group from $355.00 to $361.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Finally, Raymond James Financial set a $340.00 target price on Cigna Group in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $341.60.

Cigna Group Price Performance

Shares of Cigna Group stock opened at $279.27 on Friday. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.68. The company has a market cap of $73.79 billion, a PE ratio of 11.55, a P/E/G ratio of 1.07 and a beta of 0.29. The business has a 50 day moving average of $286.62 and a 200 day moving average of $281.14. Cigna Group has a 52 week low of $239.51 and a 52 week high of $315.47.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 EPS for the quarter, topping analysts’ consensus estimates of $7.60 by $0.18. The company had revenue of $70.04 billion during the quarter, compared to analyst estimates of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm posted $7.20 earnings per share. Cigna Group has set its FY 2026 guidance at 30.450- EPS. As a group, equities research analysts forecast that Cigna Group will post 30.5 earnings per share for the current year.

Insider Transactions at Cigna Group

In other news, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $298.61, for a total value of $268,450.39. Following the sale, the chief accounting officer directly owned 2,368 shares of the company’s stock, valued at $707,108.48. The trade was a 27.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the completion of the sale, the chief executive officer owned 34,337 shares in the company, valued at $10,054,560.34. The trade was a 85.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cigna Group

Several hedge funds have recently added to or reduced their stakes in CI. Wilkerson Advisory Group LLC bought a new position in shares of Cigna Group during the fourth quarter valued at $25,000. Cedar Mountain Advisors LLC increased its stake in Cigna Group by 161.9% during the 1st quarter. Cedar Mountain Advisors LLC now owns 110 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 68 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Cigna Group in the fourth quarter worth about $29,000. Prosperity Bancshares Inc purchased a new position in Cigna Group in the fourth quarter worth about $29,000. Finally, Creative Financial Designs Inc. ADV lifted its stake in shares of Cigna Group by 147.3% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 136 shares of the health services provider’s stock worth $37,000 after buying an additional 81 shares in the last quarter. 86.99% of the stock is owned by institutional investors.

Trending Headlines about Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook
• Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast
• Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis
• Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock.
• Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook
• Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth.

About Cigna Group

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.